-+undefined NaN%
-+undefined NaN%
-+undefined NaN%

Credit Suisse Maintains Outperform on eFFECTOR Therapeutics, Lowers Price Target to $8

Benzinga · 01/06/2023 08:06
Credit Suisse analyst Judah Frommer maintains eFFECTOR Therapeutics (NASDAQ:EFTR) with a Outperform and lowers the price target from $10 to $8.